A 'disoriented' Pain Therapeutics flips out after FDA rejects appeal on Remoxy

Pain Therapeutics has had the last word on its four-time reject Remoxy — and it’s a bitter one.

After a meeting with the FDA, the biotech says, “we believe we are no closer today to product approval than we were over a year ago” thanks to “shambolic regulations” at the agency.